Erste Asset Management GmbH Sells 10,913 Shares of Axon Enterprise, Inc $AXON

Erste Asset Management GmbH lowered its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 94.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 594 shares of the biotechnology company’s stock after selling 10,913 shares during the quarter. Erste Asset Management GmbH’s holdings in Axon Enterprise were worth $425,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. NEOS Investment Management LLC raised its position in Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after purchasing an additional 11,482 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Axon Enterprise by 3.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock worth $132,349,000 after buying an additional 5,953 shares during the period. BIT Capital GmbH grew its position in Axon Enterprise by 75.6% in the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after acquiring an additional 1,522 shares during the period. Finally, Wealthedge Investment Advisors LLC raised its stake in Axon Enterprise by 180.7% during the second quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after acquiring an additional 775 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Wall Street Analyst Weigh In

AXON has been the subject of several analyst reports. Royal Bank Of Canada cut their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. UBS Group lowered their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a research report on Tuesday, January 6th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Insider Buying and Selling

In related news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the sale, the president owned 249,502 shares of the company’s stock, valued at $137,874,805.20. This trade represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $551.92, for a total value of $5,519,200.00. Following the sale, the chief executive officer owned 3,110,997 shares in the company, valued at $1,717,021,464.24. This represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 58,040 shares of company stock worth $32,251,738 in the last ninety days. Insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $542.40 on Monday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market cap of $43.61 billion, a PE ratio of 356.84, a P/E/G ratio of 12.23 and a beta of 1.46. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91. The business’s 50-day moving average price is $537.92 and its two-hundred day moving average price is $623.54.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter in the prior year, the business earned $2.08 earnings per share. The business’s revenue for the quarter was up 38.5% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.